An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with High Risk Essential Thrombocythaemia who are Resistant to or Intolerant of Hydroxycarbamide Therapy.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519964-42-00

Acronym

STP938-301

Enrollment

Registered

2025-05-13

Start date

2025-07-02

Completion date

Unknown

Last updated

2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocythaemia

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026